• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌间歇性激素治疗模型分析及贝叶斯模型比较

Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer.

机构信息

Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

Department of Radiation Oncology, H. Lee Moffitt Cancer and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

出版信息

Bull Math Biol. 2021 Nov 19;84(1):2. doi: 10.1007/s11538-021-00953-w.

DOI:10.1007/s11538-021-00953-w
PMID:34797430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8604892/
Abstract

The prostate is an exocrine gland of the male reproductive system dependent on androgens (testosterone and dihydrotestosterone) for development and maintenance. First-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival. A significant problem with continuous ADT at the maximum tolerable dose is the insurgence of cancer cell resistance. In recent years, intermittent ADT has been proposed as an alternative to continuous ADT, limiting toxicities and delaying time-to-progression. Several mathematical models with different biological resistance mechanisms have been considered to simulate intermittent ADT response dynamics. We present a comparison between 13 of these intermittent dynamical models and assess their ability to describe prostate-specific antigen (PSA) dynamics. The models are calibrated to longitudinal PSA data from the Canadian Prospective Phase II Trial of intermittent ADT for locally advanced prostate cancer. We perform Bayesian inference and model analysis over the models' space of parameters on- and off-treatment to determine each model's strength and weakness in describing the patient-specific PSA dynamics. Additionally, we carry out a classical Bayesian model comparison on the models' evidence to determine the models with the highest likelihood to simulate the clinically observed dynamics. Our analysis identifies several models with critical abilities to disentangle between relapsing and not relapsing patients, together with parameter intervals where the critical points' basin of attraction might be exploited for clinical purposes. Finally, within the Bayesian model comparison framework, we identify the most compelling models in the description of the clinical data.

摘要

前列腺是男性生殖系统的外分泌腺,其发育和维持依赖于雄激素(睾酮和二氢睾酮)。前列腺癌的一线治疗包括雄激素剥夺疗法(ADT),剥夺正常和恶性前列腺细胞增殖和存活所需的雄激素。在最大耐受剂量下连续进行 ADT 的一个显著问题是癌细胞耐药性的出现。近年来,间歇性 ADT 已被提议作为连续 ADT 的替代方案,限制了毒性并延迟了进展时间。已经考虑了几种具有不同生物学耐药机制的数学模型来模拟间歇性 ADT 反应动力学。我们比较了 13 种这些间歇性动力学模型,并评估了它们描述前列腺特异性抗原(PSA)动力学的能力。这些模型根据局部晚期前列腺癌间歇性 ADT 的加拿大前瞻性 II 期试验的纵向 PSA 数据进行了校准。我们在治疗和非治疗期间对模型的参数空间进行贝叶斯推断和模型分析,以确定每个模型在描述患者特异性 PSA 动力学方面的优势和劣势。此外,我们对模型的证据进行了经典的贝叶斯模型比较,以确定最有可能模拟临床观察到的动力学的模型。我们的分析确定了一些具有重要能力的模型,可以区分复发和不复发的患者,以及参数区间,其中临界点的吸引域可能会被用于临床目的。最后,在贝叶斯模型比较框架内,我们确定了在描述临床数据方面最引人注目的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/7a541aef9543/11538_2021_953_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/74f0d5950dbc/11538_2021_953_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/bd2f70331f35/11538_2021_953_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/74d2b13b1f2a/11538_2021_953_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/e04f42dde7fc/11538_2021_953_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/6a71667b1d1b/11538_2021_953_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/f576bb25f669/11538_2021_953_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/7a541aef9543/11538_2021_953_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/74f0d5950dbc/11538_2021_953_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/bd2f70331f35/11538_2021_953_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/74d2b13b1f2a/11538_2021_953_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/e04f42dde7fc/11538_2021_953_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/6a71667b1d1b/11538_2021_953_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/f576bb25f669/11538_2021_953_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d1f/8604892/7a541aef9543/11538_2021_953_Fig7_HTML.jpg

相似文献

1
Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer.前列腺癌间歇性激素治疗模型分析及贝叶斯模型比较
Bull Math Biol. 2021 Nov 19;84(1):2. doi: 10.1007/s11538-021-00953-w.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.前列腺癌患者的间歇性雄激素剥夺治疗:预测治疗间歇期延长的因素。
Oncologist. 2000;5(1):45-52. doi: 10.1634/theoncologist.5-1-45.
4
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].[欧洲泌尿外科学会前列腺癌指南。第二部分:晚期、复发性及去势抵抗性前列腺癌的治疗]
Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14.
5
Intermittent androgen deprivation therapy in advanced prostate cancer.晚期前列腺癌的间歇性雄激素剥夺疗法
Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2.
6
Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.在一项开放标签、随机、3 期临床试验中,局部晚期前列腺癌患者接受新辅助内分泌和外照射放疗,然后辅助持续/间歇性内分泌治疗的肿瘤学结局。
Cancer. 2020 Sep 1;126(17):3961-3971. doi: 10.1002/cncr.33034. Epub 2020 Jun 23.
7
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).复发性或局部晚期前列腺癌患者间歇性与持续性雄激素剥夺治疗:一项3b期随机研究(冰岛研究)
Eur Urol. 2016 Apr;69(4):720-727. doi: 10.1016/j.eururo.2015.10.007. Epub 2015 Oct 29.
8
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.预测接受地加瑞克间歇性雄激素剥夺治疗的前列腺癌患者停药时间的因素。
Eur Urol Focus. 2017 Oct;3(4-5):470-479. doi: 10.1016/j.euf.2015.12.008. Epub 2016 Jan 22.
9
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.前列腺癌的间歇性雄激素剥夺疗法:基于 3 期临床试验的批判性评价。
Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19.
10
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.连续与间歇性雄激素剥夺疗法治疗转移性前列腺癌。
Urol Oncol. 2013 Jul;31(5):549-56. doi: 10.1016/j.urolonc.2011.03.008. Epub 2011 May 10.

引用本文的文献

1
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.骨生态系统促进多发性骨髓瘤复发和异质性耐药疾病的演变。
Nat Commun. 2024 Mar 19;15(1):2458. doi: 10.1038/s41467-024-46594-0.
2
Treatment of evolving cancers will require dynamic decision support.不断演变的癌症的治疗将需要动态的决策支持。
Ann Oncol. 2023 Oct;34(10):867-884. doi: 10.1016/j.annonc.2023.08.008.
3
Practical Understanding of Cancer Model Identifiability in Clinical Applications.临床应用中癌症模型可识别性的实践理解

本文引用的文献

1
Are all models wrong?所有模型都是错误的吗?
Comput Syst Oncol. 2020 Dec;1(1). doi: 10.1002/cso2.1008. Epub 2021 Jan 15.
2
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.前列腺特异性抗原动力学预测个体对间歇性雄激素剥夺的反应。
Nat Commun. 2020 Apr 9;11(1):1750. doi: 10.1038/s41467-020-15424-4.
3
Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.前列腺癌患者 PCA3 水平的诊断准确性:系统评价与荟萃分析。
Life (Basel). 2023 Feb 1;13(2):410. doi: 10.3390/life13020410.
4
Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer.转移性前列腺癌的范围界定适应性治疗
Cancers (Basel). 2022 Oct 28;14(21):5319. doi: 10.3390/cancers14215319.
5
High Accuracy Indicators of Androgen Suppression Therapy Failure for Prostate Cancer-A Modeling Study.前列腺癌雄激素抑制治疗失败的高精度指标——一项建模研究
Cancers (Basel). 2022 Aug 20;14(16):4033. doi: 10.3390/cancers14164033.
Int Braz J Urol. 2020 Sep-Oct;46(5):691-704. doi: 10.1590/S1677-5538.IBJU.2019.0360.
4
Dynamics and implications of models for intermittent androgen suppression therapy.间歇性雄激素抑制疗法模型的动态变化及影响
Math Biosci Eng. 2018 Dec 11;16(1):187-204. doi: 10.3934/mbe.2019010.
5
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.将进化动态纳入转移性去势抵抗性前列腺癌的治疗中。
Nat Commun. 2017 Nov 28;8(1):1816. doi: 10.1038/s41467-017-01968-5.
6
Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population.一般人群中年健康男性血清睾酮与前列腺特异性抗原水平之间的关联。
Curr Urol. 2017 Apr;10(1):40-44. doi: 10.1159/000447149. Epub 2017 Mar 30.
7
Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.通过基于整合患者数据的机制模型的个性化算法预测激素敏感性前列腺癌的去势抵抗时间。
Prostate. 2016 Jan;76(1):48-57. doi: 10.1002/pros.23099. Epub 2015 Sep 30.
8
Ability of intermittent androgen suppression to selectively create a non-trivial periodic orbit for a type of prostate cancer patients.间歇性雄激素抑制为一类前列腺癌患者选择性创建非平凡周期轨道的能力。
J Theor Biol. 2015 Nov 7;384:147-52. doi: 10.1016/j.jtbi.2015.08.010. Epub 2015 Aug 28.
9
Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.前列腺癌男性患者的睾酮治疗:文献综述、临床经验及建议
Asian J Androl. 2015 Mar-Apr;17(2):206-11. doi: 10.4103/1008-682X.148067.
10
Cancer stem cells: small subpopulation or evolving fraction?癌症干细胞:是一小部分亚群还是动态变化的组分?
Integr Biol (Camb). 2015 Jan;7(1):14-23. doi: 10.1039/c4ib00191e.